文献速递血栓与止血贫血与红细胞疾病

无纤溶亢进可解释氨甲环酸在低增生性血小板减少症中无效

Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.
PubMed 文献 · Blood Adv · 2023-01-01

A-TREAT试验显示氨甲环酸(TXA)在需血小板输注的严重血小板减少症患者中预防WHO 2级及以上出血不优于安慰剂。本辅助研究对115例受试者基线和稳态 trough 样本行ECLT、PG和tPA-CLT检测,未发现纤溶激活证据,TXA trough 浓度变异大且与出血严重程度不相关。

要点

  • 基线样本经ECLT或tPA-CLT均未显示纤溶激活。
  • TXA trough 浓度为0.7-10 μg/mL,个体间变异大,与出血严重程度不相关。
  • TXA 血浆水平与PG(Spearman r=-0.78)和tPA-CLT(r=0.74)强相关。

核心结论

  • 这些血小板减少症患者中未观察到纤溶激活证据。
  • 接受相同给药方案的患者间TXA trough 浓度差异显著。
  • tPA-CLT和PG与TXA药物水平相关性良好。

研究设计与样本

  • A-TREAT试验(NCT02578901)的辅助研究,采集115例受试者基线和TXA稳态 trough 时血浆。
  • 采用ECLT、PG和tPA-CLT三种方法检测整体纤溶,并用串联质谱定量TXA。

主要发现

  • 基线样本经ECLT或tPA-CLT未显示纤溶激活。
  • ECLT及PAI-1、tPA、纤溶酶原、α2-抗纤溶酶、纤溶酶-抗纤溶酶复合物水平均与WHO 2级及以上出血风险无关。
  • TXA trough 浓度为0.7-10 μg/mL,与出血严重程度不相关。
  • TXA 血浆水平与PG(Spearman r=-0.78)和tPA-CLT(r=0.74)强相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders. In this ancillary study, we sought to determine whether this clinical outcome could be explained on the basis of correlative assays of fibrinolysis. Plasma was collected from A-TREAT participants (n = 115) before the initiation of study drug (baseline) and when TXA was at steady-state trough concentration (follow-up). Global fibrinolysis was measured by 3 assays: euglobulin clot lysis time (ECLT), plasmin generation (PG), and tissue-type plasminogen activator (tPA)-challenged clot lysis time (tPA-CLT). TXA was quantified in follow-up samples by tandem mass spectrometry. Baseline samples did not demonstrate fibrinolytic activation by ECLT or tPA-CLT. Furthermore, neither ECLT nor levels of plasminogen activator inhibitor-1, tPA, plasminogen, alpha2-antiplasmin, or plasmin-antiplasmin complexes were associated with a greater risk of WHO grade 2+ bleeding. TXA trough concentrations were highly variable (range, 0.7-10 μg/mL) and did not correlate with bleeding severity, despite the fact that plasma TXA levels correlated strongly with pharmacodynamic assessments by PG (Spearman r, -0.78) and tPA-CLT (r, 0.74). We conclude that (1) no evidence of fibrinolytic activation was observed in these patients with thrombocytopenia, (2) trough TXA concentrations varied significantly between patients receiving the same dosing schedule, and (3) tPA-CLT and PG correlated well with TXA drug levels.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023. PMID: 36044391. doi:10.1182/bloodadvances.2022008255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。